Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1999-01-06
2000-05-23
Raymond, Richard L.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514285, 514463, 514772, 514946, 514947, A61K 31365, A61K 3144
Patent
active
060666455
ABSTRACT:
This invention provides for pharmaceutical formulations of compounds which are useful as protective agents when administered to patients also receiving antineoplastic drugs. The invention also includes methods of reducing the toxicity of various antineoplastic agents by administering an effective amount of the protective agent to a patient receiving one or more antineoplastic agents. The compounds useful as protective agents have either a sulfhydryl moiety or are reducible disulfides.
REFERENCES:
patent: 4310515 (1982-01-01), Granatek et al.
patent: 5789000 (1998-08-01), Hausheer et al.
Leeuwenkamp et al., European Journal of Cancer, vol. 27, No. 10, pp. 1243-1347, Oct. 1991.
Shaw, I.C. and Weeks, M.S., Excretion of Disodium Bis-2-Mercaptoethanesulphonate (Dimesna) in the Urine of Volunteers after Oral Dosing; Eur J Cancer Clin Oncology 23:933-935; 1987.
Levine, Barry S., Henry, Mary C., Port, Curtis D., Richter, Ward R., and Urbanek, Mary A.; Nephrotoxic Potential of cis-Diamminedichloroplatinum and Four Analogs in Male Fischer 344 Rats; JNCI, 67(1):210-206 Jul. 1981.
Arrick, Bradley A., et al. Glutathione Metabolism as a Determinant of Therapeutic Efficacy: A Review. Cancer Research, 44: 4224-4232, Oct. 1984.
Andrews, Paul A., et al. Metallothionein-mediated cisplatin resistance in human ovarian carcinoma cells. Cancer Chemother Pharmacol, 19: 149-154, 1987.
Bajorin, Dean F., et al. Pharmacokinetics of cis-Diamminedichloroplatinum(II) after Administration in Hypertonic Saline. Cancer Research, 46: 5969-5972, Nov. 1986.
Borch, Richard F., et al. Effect of diethyldithiocarbamate rescue on tumor response to cisplatinum in a rat model. Proc. Natl. Acad. Sci. USA, 77: 5441-5444, Sep. 1980.
Brock, N., The Development of Mesna for the inhibition of Urotoxic Side Effects of Cyclophosphamide, Ifosfamide, and Other Oxazaphosphorine Cytostatics. Rec. Res. Cancer Res., 74: 20-278, 1980.
Brock, Norbert, et al., Studies on the Urotoxicity of Oxazaphosphorine Cytostatistics and its Prevention. Eur. J. Cancer clin. Oncol., 17: 1155-1163, 1981.
Brock, Norbert, et al., Studies on the Urotoxicity of Oxazaphosphorine Cytostatistics and its Prevention--III. Profile of Action of Sodium 2-mercaptoethane Sulfonate (Mesna). Eur. J. Cancer Clin. Oncol., 18(12): 1377-1387, 1982.
Brock, Von N., et al., Arzneim Forsch 32: 486-487 (1982).
Brock, N., et al., Pharmacokinetcis and Mechanism of Action of Detoxifying Low-Molecular-Weight Thiols. J. Cancer Res. Clin. Oncol., 108: 87-97, 1984.
Brock, Norbert, et al., The development of mesna for regional detoxification. Cancer Treatment Reviews, 10(Suppl. A): 33-43, 1983.
Burkert, Hans, et al., Clinical overview of mesna. Cancer Treatment Reviews, 10(Suppl. A): 175-181, 1983.
Burkert, H., et al., Bioavailability of Orally Administered Mesna. Arzneim-Forsch./Drug Res., 34:(II), 1597-1600, 1984.
Campbell, A. Bruce, et al., Plasma Platinum Levels: Relationship to Cisplatin Dose and Nephrotoxicity. Cancer Treatment Reports, 67(2): 169-172, Feb. 1983.
Choie, D. David, et al., Acute and Chronic Cisplatin Nephropathy in Rats. Laboratory Investigation, 44(5): 397-402, 1981.
Daugarrd, Gedske, et al., Cisplatin nephrotoxicity a review. Cancer Chemother. Pharmacol., 25: 1-9, 1989.
DeConti, Ronald C., et al., Clinical and Pharmacological Studies with cis-Diamminedichloroplatinum(II). Cancer Research, 33: 1310-1315, Jun. 1973.
Dentino, Mariellen, et al., Long Term Effect of Cis-Diamminedichloride Platinum (CDDP) on Renal Function and Structure in Man. Cancer, 41(4): 1274-1281, Apr. 1978.
Earhart, Robert H., Instability of cis-Dichlorodiammineplatinum in Dextrose Solution. Cancer Treatment Reports, 62(7): 1105-1106, Jul. 1978.
Eastman, Alan, Gluthathione-mediated activation of anticancer platinum (IV) complexes. Biochemical Pharmacology, 36(23): 4177-4178, 1987.
Eastman, Alan, Reevaluation of Interaction of cis-Dichloro(ethylenediamine)platinum(II) with DNA. Biochemistry, 25: 3912-3915, 1986.
Glover, Donna, et al., WR-2721 and High-Dose Cisplatin: An Active Combination in the Treatment of Metastatic Melanoma. Journal of Clinical Oncology, 5(4): 574-578, Apr., 1987.
Goldstein, Robin S., et al., The Nephrotoxicity of Cisplatin. Life Sciences, 32: 685-690, 1983.
Gonzalez-Vitale, Juan C., et al., The Renal Pathology in Clinical Trials of Cis-Platinum (II)Diamminedichloride. Cancer, 39: 1362-1371, 1977.
Hayes, Daniel M., et al., High Dose Cis-Platinum Diammine Dichloride, Amelioration of Renal Toxicity by Mannitol Diuresis. Cancer, 39: 1372-1381, 1977.
Howell, Stephen B., et al., Intraperitoneal Cisplatin with Systemic Thiosulfate Protection. Annals of Internal Medicine, 97: 845-851, 1982.
Hegedus, L., et al., Chemical reacitivity of cisplatin bound to human plasma proteins. Cancer Chemother. Pharmacol., 20: 211-212, 1987.
Jacobs, Charlotte, et al., Renal Handling of cis-Diamminedichloroplatinum(II). Cancer Treatment Reports, 64(12): 1223-1226, Dec. 1980.
James, C.A., et al., Estimation of mesna and dimesna in plasma and urine by high-performance liquid chromatography with electrochemical detection. Journal of Chromatography, 382: 394-398, 1986.
Jocelyn, Biochemistry of the SH Group. Academic Press, London, New York, 1972.
Kelley, Susan L., et al., Overexpression of Metallothionein Confers Resistance to Anticancer Drugs. Science, 241: 1813-1815, Sep. 1988.
Kempf, S.R., et al., Effective prevention of the nephrotoxicity of cis-platin (CDDP) by administration of sodium 2-mercaptoethane-sulfonate (MESNA) in rats. Br. J. Cancer, 52: 937-939. 1985.
Kociba, Richard J., et al., Acute Toxicologic and Pathologic Effects of Cis-Daimminedichloroplatinum (NSC-119875) in the Male Rat. Cancer Chemotherapy Reports, 55:1-8 Feb. 1971.
Lemaire, Henry, et al., The Synthesis of 2-Mercaptoethane-sulfonamide. J. Org. Chem., 26: 1330-1331, Apr. 1961.
Markman, Maurie, Interperitoneal Chemotherapy. Seminars in Oncology, 18(3): 248-254, Jun. 1991.
Leonard, B.J., et al., Antileukaemic and Nephrotoxic Properties of Platinum Compounds. Nature, 234: 43-45, Nov. 1971.
Offerman, Joop J.G., et al., Acute effects of cis-diamminedichloroplatinum (CDDP) on renal function. Cancer Chemother. Pharmacol., 12: 36-38, 1984.
Ormastad, Kari, et al., Pharmacokinetics and Metabolism of Sodium 2-Mercaptoethanesulfonate in the Rat. Cancer Research, 43: 333-338, Jan. 1983.
Ostrow, S., et al., High-Dose Cisplatin Therapy Using Mannitol Versus Furosemide Diuresis: Comparative Pharmacokinetics and Toxicity. Cancer Treatment Reports, 65: 73-78, 1981.
Ozols, Robert F., et al., High-dose Cisplatin in Hypertonic Saline. Annals of Internal Medicine, 100: 19-24, 1984.
Pfeifle, Craig E., et al., High-Dose Cisplatin with Sodium Thiosulfate Protection. Journal of Clinical Oncology, 3(2): 237-244, Feb. 1985.
Pinto, Ann L., et al., Binding of the Antitumor Drug cis-Diamminedichloroplatinum (II) (Cisplatin) to DNA. Biochimica et Biophysica Acta., 780: 167-180, 1985.
Pohl, Von J., et al., Meth. Find. Clin. Pharmacol. 3(Supp. 1): 95-101, 1981.
Perry, M.C., The Chemotherapy Source Book, Williams and Wilkins, 1172 pp., 1992.
Reed, Eddie, et al., Platinum Analogues in Cancer Chemotherapy, Principles and Practice, 465-490, 1990.
Rosenberg, Barnett, et al., Platinum Compounds: A New Class of Potent Antitumor Agents. Nature, 222: 385-386, Apr. 1969.
Rozencweig, Marcel, et al., Cis-diamminedichloroplatinum (II) A New Anticancer Drug. Annals of Internal Medicine, 86: 803-812, 1977.
Safirstein, Robert, et al., Cisplatin Nephrotoxocity. American Journal of Kidney Diseases, 8(5): 356-367, Nov. 1986.
Sidau, Beate, et al., Determination of sodium 2-mercaptoethanesulphonate by high-performance liquid chromatography using post-column reaction colorimetry or electrochemical detection. Journal of Chromatography, 311: 234-238, 1984.
Symposium: Cisplatin: Contemporary Treatment Approaches. Seminars in Oncology, 16(Suppl. 6): 1-128, 1989.
Thomson, A.J., The Interactions of Platinum Compounds with Biological Molecules. Rec. Res. Cancer Res., 48: 38-62, 1974.
Dodd Thomas J.
Hausheer Frederick H.
BioNumerik Pharmaceuticals, Inc.
Dodd Thomas J.
Raymond Richard L.
LandOfFree
Formulations and methods of reducing toxicity of antineoplastic does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Formulations and methods of reducing toxicity of antineoplastic , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Formulations and methods of reducing toxicity of antineoplastic will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1837304